Market Place
Sourcing Support
Tricida files for Chapter 11 bankruptcy protection as it searches for a buyer
13 Jan 2023 //
PROACTIVE INVESTORS
Adamis, Harpoon, Neoleukin and Tricida grow biotech layoff wave
15 Nov 2022 //
FIERCEBIOTECH
Tricida Announces Third Quarter 2022 Financial Results
14 Nov 2022 //
BUSINESSWIRE
Tricida eyeing sale, cost-cutting options after failing high-stakes CKD wager
03 Nov 2022 //
ENDPTS
Tricida Provides Strategic Update
02 Nov 2022 //
BUSINESSWIRE
Phase 3 fail seals fate of Tricida`s FDA-rejected kidney drug
25 Oct 2022 //
FIERCEBIOTECH
Tricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer
24 Oct 2022 //
PRESS RELEASE
Tricida Announces $125 Million Debt Facility with Hercules Capital
19 Oct 2022 //
BUSINESSWIRE
Tricida Announces the Selection of the VALOR-CKD Trial for an Oral Presentation
03 Oct 2022 //
BUSINESSWIRE
Tricida to Present at the H.C. Wainwright 24th Global Investment Conference
06 Sep 2022 //
BUSINESSWIRE
Tricida Announces Second Quarter 2022 Financial Results
08 Aug 2022 //
BUSINESS WIRE
Tricida to Report Second Quarter Financial Results
01 Aug 2022 //
GLOBENEWSWIRE
Tricida slams brakes on a pivotal trial early while planning a run at the FDA
20 May 2022 //
ENDPTS
Tricida Announces First Quarter 2022 Financial Results
10 May 2022 //
GLOBENEWSWIRE
Tricida to Report First Quarter Financial Results and Host Conference Call
03 May 2022 //
GLOBENEWSWIRE
Tricida to Present at the Needham Virtual Healthcare Conference
01 Apr 2022 //
GLOBENEWSWIRE
Tricida Announces Fourth Quarter and Full Year 2021 Financial Results
29 Mar 2022 //
GLOBENEWSWIRE
Tricida to Report Q4 Financial Results and Webcast on Tuesday, March 29, 2022
16 Mar 2022 //
GLOBENEWSWIRE
Tricida Provides Update on Timing of Top-Line Data for the VALOR-CKD Trial
02 Mar 2022 //
GLOBENEWSWIRE
Tricida to Participate in Cowen 42nd Annual Health Care Conference
01 Mar 2022 //
GLOBENEWSWIRE
Tricida to Present at two Virtual Conference
04 Jan 2022 //
GLOBENEWSWIRE
Tricida Granted Additional U.S. Patent Covering Composition of Matter
03 Mar 2021 //
GLOBENEWSWIRE
Tricida Provides Update on FDA Interactions
26 Feb 2021 //
GLOBENEWSWIRE
Tricida Provides Update on FDA Interactions
26 Feb 2021 //
GLOBENEWSWIRE
Tricida Announces Updates on Veverimer Development Program, Regulatory
08 Dec 2020 //
GLOBENEWSWIRE
Tricida Provides Update on FDA Interactions
30 Oct 2020 //
BUSINESSWIRE
Tricida Announces Twelve Data Presentations on Veverimer and Metabolic Acidosis
09 Oct 2020 //
BUSINESSWIRE
Tricida Receives Complete Response Letter from the FDA for its NDA for Veverimer
26 Aug 2020 //
BUSINESSWIRE
Tricida sinks as FDA rejection raises prospect of new trial
25 Aug 2020 //
FIERCEBIOTECH
Tricida to Present at the Goldman Sachs Virtual Healthcare Conference
02 Jun 2020 //
BUSINESSWIRE
Tricida Announces Proposed Offering of $175 M Convertible Senior Notes Due 2027
19 May 2020 //
BUSINESSWIRE
Tricida Announces Multiple Data Presentations to Be Given at the Virtual Kidney
05 Apr 2020 //
GLOBENEWSWIRE
Durable, safe and effective long-term kidney drug data from Tricida fuel
30 Mar 2019 //
ENDPTS
Comparing This Year`s Big Biotech IPOs to Previous Years
06 Nov 2018 //
BIOSPACE
Tricida files for $150M IPO to fund kidney disease drug approval
05 Jun 2018 //
FIERCE BIOTECH
Hours after filing $150M IPO, Tricida shares +ve Ph3 results on CKD drug
05 Jun 2018 //
ENDPTS
